search button
Open Access

Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow‑up

  • Authors:
    • Karen Belkić
    • Sonia Andersson
    • Susanna Alder
    • Miriam Mints
    • David Megyessi

  • View Affiliations

  • Published online on: August 25, 2022     https://doi.org/10.3892/ol.2022.13477
  • Article Number: 357

  • Copyright : © Belkić et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The incidence of adenocarcinoma‑in‑situ (AIS) of the uterine cervix is rising, with invasive adenocarcinoma becoming increasingly common relative to squamous cell carcinoma. The present study reviewed a cohort of 84 patients first‑time treated by conization for histologically‑confirmed AIS from January 2001 to January 2017, to identify risk factors associated with recurrent/persistent AIS as well as progression to invasive cervical cancer. Nearly 80% of the patients were age 40 or younger at conization. Endocervical and ectocervical margins were deemed clear in 42 of the patients. All but two patients had ≥1 follow‑up, with post‑conization high‑risk human papilloma virus (HPV) results documented in 52 patients. Altogether, 12 histopathologically‑confirmed recurrences (14.3%) were detected; two of these patients had microinvasive or invasive carcinoma. In three other patients cytology showed AIS, but without recorded histopathology. Eight patients underwent hysterectomy for incomplete resection very soon after primary conization; they were not included in bivariate or multivariate analyses. Having ≥1 post‑follow‑up positive HPV finding yielded the highest sensitivity for histologically‑confirmed recurrence: 87.5 [95% confidence interval (CI) 47.4‑99.7]. Current or historical smoking status provided highest specificity: 94.4 (95% CI 72.7‑99.9) and overall accuracy: 88.0 (95% CI 68.8‑97.5) for histologically‑confirmed recurrence. With multiple logistic regression (MLR), adjusting for age at conization and abnormal follow‑up cytology, positive HPV18 was the strongest predictor of histologically‑confirmed recurrence (P<0.005). Having ≥2 positive HPV results also predicted recurrence (P<0.02). Any unclear margin yielded an odds ratio 7.21 (95% CI 1.34‑38.7) for histologically‑confirmed recurrence adjusting for age, but became non‑significant when including abnormal cytology in the MLR model. The strong predictive value of HPV, particularly HPV18 and persistent HPV positivity vis‑à‑vis detected recurrence indicated that regular HPV testing for patients treated for AIS is imperative. In conclusion, furthering a participatory approach, including attention to smoking with encouragement to attend needed long‑term follow‑up, can better protect these patients at high risk for cervical cancer.
View References

Related Articles

Journal Cover

October-2022
Volume 24 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Belkić K, Andersson S, Alder S, Mints M and Megyessi D: Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow‑up. Oncol Lett 24: 357, 2022
APA
Belkić, K., Andersson, S., Alder, S., Mints, M., & Megyessi, D. (2022). Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow‑up. Oncology Letters, 24, 357. https://doi.org/10.3892/ol.2022.13477
MLA
Belkić, K., Andersson, S., Alder, S., Mints, M., Megyessi, D."Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow‑up". Oncology Letters 24.4 (2022): 357.
Chicago
Belkić, K., Andersson, S., Alder, S., Mints, M., Megyessi, D."Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow‑up". Oncology Letters 24, no. 4 (2022): 357. https://doi.org/10.3892/ol.2022.13477